Deltec Asset Management LLC acquired a new position in Alimera Sciences, Inc. (NASDAQ:ALIM – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 124,169 shares of the biopharmaceutical company’s stock, valued at approximately $690,000. Deltec Asset Management LLC owned approximately 0.24% of Alimera Sciences at the end of the most recent quarter.
Other hedge funds have also recently made changes to their positions in the company. Fifth Lane Capital LP bought a new stake in Alimera Sciences in the 1st quarter valued at about $83,000. Hillsdale Investment Management Inc. bought a new stake in Alimera Sciences in the 1st quarter valued at about $169,000. Ancora Advisors LLC bought a new stake in Alimera Sciences in the 1st quarter valued at about $915,000. Finally, Vanguard Group Inc. increased its position in Alimera Sciences by 61.1% in the 1st quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock valued at $4,077,000 after buying an additional 396,506 shares in the last quarter. 99.83% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of equities analysts have issued reports on the company. StockNews.com assumed coverage on Alimera Sciences in a research note on Tuesday. They set a “hold” rating for the company. Alliance Global Partners reiterated a “neutral” rating on shares of Alimera Sciences in a research note on Tuesday, June 25th. HC Wainwright downgraded Alimera Sciences from a “buy” rating to a “neutral” rating and set a $6.00 price target for the company. in a research note on Tuesday, June 25th. Finally, Maxim Group reaffirmed a “hold” rating on shares of Alimera Sciences in a report on Tuesday, June 25th.
Alimera Sciences Stock Performance
Shares of ALIM stock traded down $0.01 on Wednesday, hitting $5.59. 64,304 shares of the stock were exchanged, compared to its average volume of 209,006. The company has a current ratio of 2.62, a quick ratio of 2.51 and a debt-to-equity ratio of 1.71. The firm has a market capitalization of $292.85 million, a PE ratio of -3.56 and a beta of 1.28. Alimera Sciences, Inc. has a one year low of $2.61 and a one year high of $5.65. The firm’s 50 day moving average is $4.91 and its two-hundred day moving average is $4.06.
Alimera Sciences (NASDAQ:ALIM – Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). The company had revenue of $27.00 million for the quarter, compared to analysts’ expectations of $25.76 million. Alimera Sciences had a negative return on equity of 53.49% and a negative net margin of 23.74%. Sell-side analysts expect that Alimera Sciences, Inc. will post -0.13 earnings per share for the current fiscal year.
Alimera Sciences Profile
Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).
Featured Articles
- Five stocks we like better than Alimera Sciences
- How to Effectively Use the MarketBeat Ratings Screener
- Brinker International’s Price Dip is an Appetizing Entry Point
- What is the Hang Seng index?
- 3 Stocks That Could Beat the September Blues
- Using the MarketBeat Stock Split Calculator
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.